Teladoc Health (NYSE:TDOC) CEO Sells 17,805 Shares of Stock

Teladoc Health, Inc. (NYSE:TDOC) CEO Charles III sold 17,805 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the completion of the transaction, the chief executive officer owned 465,535 shares in the company, valued at $2,839,763.50. The trade was a 3.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Teladoc Health Price Performance

Shares of NYSE TDOC traded up $0.35 during mid-day trading on Monday, reaching $6.51. 3,469,307 shares of the company’s stock were exchanged, compared to its average volume of 5,269,782. The firm has a 50-day moving average price of $7.51 and a two-hundred day moving average price of $6.76. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -6.57 and a beta of 2.12. Teladoc Health, Inc. has a 52 week low of $4.40 and a 52 week high of $9.89.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%.The business had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. During the same quarter in the prior year, the business earned ($0.19) earnings per share. Teladoc Health’s revenue for the quarter was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, sell-side analysts forecast that Teladoc Health, Inc. will post -0.9 EPS for the current fiscal year.

Institutional Trading of Teladoc Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ABS Direct Equity Fund LLC bought a new position in Teladoc Health in the 2nd quarter worth about $1,513,000. WINTON GROUP Ltd increased its position in shares of Teladoc Health by 402.4% during the second quarter. WINTON GROUP Ltd now owns 227,100 shares of the health services provider’s stock valued at $1,926,000 after buying an additional 181,900 shares during the period. Nykredit A S bought a new stake in shares of Teladoc Health during the second quarter valued at about $27,000. HighTower Advisors LLC lifted its holdings in shares of Teladoc Health by 20.8% in the second quarter. HighTower Advisors LLC now owns 16,808 shares of the health services provider’s stock worth $143,000 after buying an additional 2,893 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Teladoc Health in the second quarter worth about $1,447,000. 76.82% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on TDOC shares. Canaccord Genuity Group lowered their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Citigroup cut their target price on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research report on Monday, August 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Finally, Bank of America boosted their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Teladoc Health currently has a consensus rating of “Hold” and a consensus price target of $7.54.

About Teladoc Health

Teladoc Health, Inc is a virtual healthcare company that provides telehealth services and technology to individuals, employers, health plans, health systems and other organizations. Its platform enables patients to connect with healthcare professionals remotely through phone, video and digital tools, supporting access to medical care across a range of specialties.

The company’s offerings include general medical consultations, mental health services through BetterHelp, expert medical opinions, chronic condition management and digital health programs.